Atıf Formatları
The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

R. B. ÖZGÜL ÖZDEMİR Et Al. , "The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer," 14th CIMT Meeting, Association For Cancer Immunotherapy , vol.1, Mainz, Germany, pp.294, 2016

ÖZGÜL ÖZDEMİR, R. B. Et Al. 2016. The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer. 14th CIMT Meeting, Association For Cancer Immunotherapy , (Mainz, Germany), 294.

ÖZGÜL ÖZDEMİR, R. B., ÖZDEMİR, A. T., KIRMAZ, C., OLTULU, F., YİĞİTTÜRK, G., & Kurt, K., (2016). The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer . 14th CIMT Meeting, Association For Cancer Immunotherapy (pp.294). Mainz, Germany

ÖZGÜL ÖZDEMİR, RABİA Et Al. "The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer," 14th CIMT Meeting, Association For Cancer Immunotherapy, Mainz, Germany, 2016

ÖZGÜL ÖZDEMİR, RABİA B. Et Al. "The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer." 14th CIMT Meeting, Association For Cancer Immunotherapy , Mainz, Germany, pp.294, 2016

ÖZGÜL ÖZDEMİR, R. B. Et Al. (2016) . "The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer." 14th CIMT Meeting, Association For Cancer Immunotherapy , Mainz, Germany, p.294.

@conferencepaper{conferencepaper, author={RABİA BİLGE ÖZGÜL ÖZDEMİR Et Al. }, title={The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer}, congress name={14th CIMT Meeting, Association For Cancer Immunotherapy}, city={Mainz}, country={Germany}, year={2016}, pages={294} }